Estrogen replacement therapy and morbidity and mortality after percutaneous coronary intervention  by Gruberg, Luis et al.
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1148-24 Estrogen Replacement Therapy and Morbidity and 
Mortality After Percuteneous Coronary Intervention 
Luis Grub~rg, Angels Silverman, Ellen E. Pinnow, William O. Suddath, Lowell I~ Satler, 
John R. Laird, Jr., Augusto D. Pichard, Kenneth M. Kent, Joseph Lindsay, Jr., Ron 
Waksman, Washington Hospital Center, Washington, Dist. of Columbia, Rambam 
Medical Center, Hails, Israel. 
Background: Most observational studies suggested that postmenopausal estrogen 
replacement therapy (ERT) reduces the risk of cardiovascular events. The results of the 
HERS study have called this conclusions into question in women with established coro- 
nary artery disease. Methods: A total of 1,365 female patients aged between 60 and 70 
years-old (mean 63), underwent percutaneous coronary intervention between 1/1994 
and 112000. A total of 225 of them were on ERT at the time of the procedure and t ,140 
were not. Results: Patients on ERT were younger (61 years-old vs. 63 years old, 
p<0.001), had a higher incidence of unstable angina (70% vs. 64%, p=0.04, had prior 
pemutaneous coronary intervention (55% vs. 48%, p=0.04) and had a positive family his- 
tory of coronary artery disease (74% vs. 61%, p<0.001 ). Clinical and angiographic suc- 
cess rates were similar in beth groups. In-hospital major adverse cardiac events (death, 
myocardial infarction and emergency coronary artery bypass surgery) were similar in 
both groups (1.5% vs. 2.5%, p=NS). One-year outcomes are shown in the Table. Con- 
clualons: Female patients with coronary artery disease on ERT had significantly lower 
one-year mortality rates compared to those who were not on ERT. This treatment did not 
seem to affect coronary artery disease progression, as reflected by higher target lesion 
and target vessel revasculadzation rates. We have to take into account the retrospective 
nature of the study and the fact that patients on ERT might have led healthier lifestyles. 
Table 1. One-year Outcome 
ERT (n=225) No ERT (n=1,140) p 
Myocardial infarction 7.8 % 5.9 % 0.3 
Target lesion revascularization 17 % 12 % 0.04 
Target vessel revasculadzation 21% 15 % 0.049 
Death 1.5 % 5.0 % 0.02 
1148-25 Predictors of Six-Month Clinical Outcome After Bal loon 
Angioplasty to Guide Provisional Stent Implantation 
Rob A. van Lieberoen, Michiel Voskuil, Jan G. Tijssen, Patrick W. Serruys, Jan J. Piek, 
Academic Medical Center, Amsterdam, The Netherlands, Thorax Center Rotterdam, 
Rotterdam, The Netherlands. 
Background. The DEBATE I study identified a distal coronary flow reserve (CFR) <2.5 
in combination with a diameter stanosis (DS) <35% after balloon angioplasty (BA) as a 
modest predictor for 6 month clinical outcome. 
Methods. Patient characteristics, angiographic and physiological characteristics of the 
DEBATE 1 and 2 trials were analyzed before and after BA in 416 patients without pri- 
mary-, bailout- or adjunctive-stanting. Distal CFR was defined as the ratio of adenosine- 
induced hyperemic average peak velocity (APV) / baseline-APV assessed by a Doppler 
guide wire. Major adverse cardiac events (MACE), i.e. death, myocardial infarction or tar- 
get lesion revascularization (TLR), were analyzed for the first 6 months. 
Results. MACEs occurred in 22.4%, 10.3% and 5.9% of patients treated by BA (n=416), 
primary stanting (n=97) and adjunctive stant implantation (n=188). Multiple logistic 
regression analysis revealed DS ~30% after BA, baseline-APV ~20 cm/s, and CFR <1.8 
before BA as independent predictors for MACE after BA. Clinical outcome in patients 
with none or a single risk factor (53% of the patients treated with BA) was similar to that 
in patients with primary stant implantation (14% vs 10.3% MACE, P= 0.4). 
Conclusion,=, Pre-procedural Doppler variables and residual diameter stanosis after BA 
are independent predictors of clinical outcome. Patients with none or one risk factor 
treated with balloon angioplasty ield a clinical outcome similar to that after primary stent 
implantation. 
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1148-26 Stenting Very Smell (<2 mm) Coronary Artery Lesions 
Ehud Grenadier, Ariel Ronuin, Isaac Hertz, Benjamin Peled, Monther Boulos, Eugenia 
Nikolsky, Shlomo Amikam, Artur Karner, Majdi Halabi, Rafael Beyar, Rambam Medics/ 
Center, Hails, Israel. 
Background: Published data regarding stenting in very small arteries is still limited. The 
feasibility, safety, and efficacy of implantation of the 2.0 mm coated coronary stent were 
prospectively studied. 
Methods and Results: We studied 123 consecutive patients, from 3 centers, who under- 
went elective (92%) or bail-out insertion of 147 BiodivYsio mini stents (2.0 mm) in 135 
lesions. Clinical follow-up was obtained in 119/123 (97%) patients at one month and 104/ 
123 (84%) patients at 11 months. Successful optimal stent deployment was achieved in 
126/135 lesions. Minimum luminal diameter increased from 0.36.t:0.36 mm to 1.91_+0.7 
mm and diameter stanosis decreased from 91_+7% to 5.1_+3%. There were no in-hospital 
deaths, one patient had acute stent thrombosis associated with Q-wave myocardial inf- 
arction. In the following 11 months there was one additional MI and one patient was 
referred to CABG. Coronary Angiography due to chest pain or significant ischemia was 
performed in 21 patients. Of them, 7121 (33%) of the small vessel PC stent group 
required PCI. Most patients improved in their clinical symptoms. The rate of major 
adverse cardiac events was 6.7% in 11 months follow up. 
Conclusion: This initial clinical experience indicates that the implantation of 2.0 mm 
stonts coated with phosphorylcholine appears to be safe and efficacious in the treatment 
of complex coronary lesions and is associated with low target vessel revascularization 
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1149-11 Direct Implantation of Self-Expanding Stent for Acute 
Coronary Syndromes 
Toumoki Ohar~, Shinsuke Nanto, Ryuichi Morozumi, Tetuya Watanabe, Mayu Nishio, 
Department of Cardiology, Amagasaki, Japan. 
Backgrounds: During percutaneus coronary intervention, distal embolization of plaque 
debris is often experienced immediately after dilation of large remodeled and lipid dch 
plaque in native coronary arteries who have acute coronary syndrome (ACS). Direct self- 
expanding stent with low-pressure dilation potentially reduce the risk of embolization. 
Methods: To evaluate the efficacy of direct implantation of self-expanding stant compared 
with balloon-expandable stent for unstable plaque, we randomly assigned 54 patients 
who had unstable angina to receive either self-expanding stant (5 atm post dilation; 
RADIUS TM, n=22) or balloon-expanding stont (12 atm x 60 sac; $670, n=32) and aspi- 
rated blood samples from distal coronary arteries of target lesions using RESCUE TM 
thrombectomy systems immediately after direct stanting and conducted microscopic 
analysis of aspirated matedals. All cases were studied the plaque morphology with intra- 
vascular ultrasound (IVUS) before stanting. Results; In RADIUS TM group, there was no 
patients who showed angiographic flow reduction and microscopic plaque debris. On the 
other hand in $670 group, 8 patients (25 %)showed transient flow reduction during the 
procedure and macrophages with blood call agglutination were observed in their aspi- 
rated materials. Stant cross section area(CSA) and lumen CSA of RADIUS TM increased 
from 7.35±1.09,8.04±1.89mrrF immediately after implantation to 
9.38±3.40mm~,7.96±2.49 three month after (p<0.01).Conclusions: When treatment of 
unstable plaque, RADIUS TM implantation with low pressure post dilation decreases the 
incidence of flow reduction compared with balloon-expanding stant and expands continu- 
ously after implantation. Direct implantation of serf-expanding stent is useful for interven- 
tion of unstable plaque. 
1149-12 Coronary Heart Disease Stanting In Small  Vessels 
Versus Balloon Angioplasty Study (CHIVAS): A 
Randomized Prospective Multicenter Trial 
Toshiva Muramatsu. Kohicbiro IwasakL Naoto Inoue, Yuhki Horita, Takahiro Tanaka, 
Naoya Fujita, Haruo Kamiya, Masanobu Namure, Kojiro Awano, Mikitaka Murakami, 
Yukio Ozaki, Alexandra Lansky, Kawasaki Social Insurance Hospital, Kawasaki, Japan. 
Background: Since no clear conclusions have been drawn regarding the safety and effi- 
cacy of stanting in small coronary vessels other than ATC, CHIVAS (Coronary Heart Dis- 
ease Stanting In Small Vessels vs Balloon Angioplasty Study), a prospective, 
randomized, muiticantar (23 sites) study which compared the long-term outcome of ACS 
MULTI-LINK stenting and POBA in small vessels was conducted. 
Methods: A total of 302 patients (pts) with de novo or 1st restenotic lesions of native cor- 
onary arteries of < 3 mm and lesion lengths of <15mm were enrolled. The pts were ran- 
domized into two groups: a stanting arm (SA: 148 pts) and a POBA arm (BA: 154 pts). 
Diabetic pts made up 51.4% (71/148) of the SA and 48.6% (67/154)of the BA. A follow- 
up angiograph was conducted at six-months. 
Results: Of the 302 pt cohort, 19 pts were excluded from the analysis as 11 BA pts 
received bail-out stentings and 8 SA pts deployed stents other than MULTI-LINK. Of the 
283 per protocol pts, 241 pts completed pre- and post-procedure OCA analysis (SA: 121, 
BA: 120) and 42 are still under analysis. The interim analysis of the 241 pts yielded no 
significant differences in baseline patient/lesion characteristics between the SA and the 
BA arms. Reference lumen diameter and the lesion length for the SA were 2.39=0,43 
mm and 11.23±3.18 mm, respectively while those for the BA were 2.35±0.41 mm and 
11.10±5.01 mm, respectively. The lesion minimal umen diameter (MLD) increased from 
0.68±0.36 mm to 1.78=0.36 mm in the SA and from 0.70~0.36 mm to 1.56=0.31 mm in 
the BA (p<0.001). The lesion acute gain was 1.10±0.38 mm in the SA and 0,86~0.41mm 
in the BA (p<0.001). In the 130 pts (SA: 68, BA: 62) who completed the follow-up QCA 
thus far, the lesion binary restenosis rate at 6 months was 29% in the SA and 44% in the 
BA (p=0.041). In the total of 186 pts who have had their clinical data analyzed, the target 
lesion revascularization rate (TLR) up to 6 months was 10.3% (10/97) in the SA and 
19.2% (19/89) in the BA (p=0.089). 
Conclusion: Our preliminary results showed that the stanted pts exhibited lower rates of 
binary restenosis and TLR versus the POBA pts. A final analysis of data including all pts 
will be presented at the meeting. 
